title: [Anti-PD-1 Antibody Drugs - Potential of Plasma PD-L1 Protein as a Biomarker].
abstract: The superior therapeutic effects of antibodies targeting immune checkpoints have been reported in the treatment of various cancers including non-small cell lung cancer(NSCLC)and malignant melanoma. However, the risk of reactivity against selfantigens and the high prices of these drugs are major concerns. Previously, PD-L1 protein expression and the number of infiltrating T cells in tumor tissues were investigated by immunohistochemical staining, as biomarkers for therapeutic anti-PD- 1 antibodies. However, further research into the clinical significance of PD-L1 expression in tumor tissues is still required. A promising and comprehensive gene mutation analysis of tumor tissues and T cell repertoire analysis has recently been undertaken. Liquid biopsy, which has the benefit of being minimally invasive, has also been investigated. We are currently, investigating the utility of plasma PD-L1 protein levels as a predictive biomarker of prognosis in NSCLC. Furthermore, it is important to explore useful biomarkers and develop reliable companion diagnostics for the individualized treatment with immune checkpoint drugs.
authors.affiliation: Dept. of Surgery, Teikyo University School of Medicine.
authors.forename: Hisae
authors.initials: H
authors.lastname: Iinuma
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Matsutani
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Uehara
authors.forename: Masafumi
authors.initials: M
authors.lastname: Kawamura
mesh_terms: D000906:Antibodies / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001706:Biopsy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000473:pathology; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology*; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000906:Antibodies; D060890:B7-H1 Antigen; D014408:Biomarkers, Tumor; C423236:CD274 protein, human; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor